Jack A. Khattar
President & CEO

The founder of Supernus Pharmaceuticals, Mr. Khattar, has 20 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies.

Prior to founding Supernus, and for more than 6 years, Mr. Khattar served as a Board member, President and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Mr. Khattar joined Shire from CIMA, a drug delivery company that is currently a division of Cephalon, where he last served as an Executive Officer and the Chairman of the Management Committee. At CIMA he was also responsible for business development including the licensing of CIMA's technologies, corporate alliances and strategic planning.

Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in the US, Europe and the Middle East.

In 1985, he received his MBA from the Wharton School of the University of Pennsylvania. He is a Board member of Rockville Economic Development Inc.

David A. Theil, CPA
Chief Financial Officer

Mr. Theil joined Supernus Pharmaceuticals as the Chief Financial Officer. Mr. Theil's career of more than 25 years includes a Big 4 CPA firm and then several high technology companies in private accounting. Most recently, Mr. Theil served as Chief Financial Officer for a biotechnology company and previous to that at a telecommunications firm. At these posts, he was responsible for all aspects of finance, accounting, administration and human resources. For the 10 previous years, Mr. Theil served as Corporate Treasurer at IGEN International, Inc., a biotechnology company. He helped take the Company public and then managed in the post-SEC environment for five of those years.

Mr. Theil began his career at Deloitte & Touche as a Manager of Emerging Business Markets Group, where he served clients in biotechnology, communications, healthcare and other technology sectors as well as founding the local DC computer consulting group for the firm. Mr. Theil obtained his BSc in Accounting and Finance in 1982 from Indiana University and completed his CPA exam in the same year.

Woody Bryan, Ph.D.
Vice President of Business Development and Project Management

In 1991, Dr. Bryan joined the pharmaceutical industry as a Senior Scientist with Schering Plough and then worked in Business Development at AAI from 1994 – 2000 where he was Global Product Director for Pharmaceutics.

He joined Shire in January 2000 where he served as Vice President Business Development for Shire Laboratories, the Advanced Drug Delivery Division of Shire Pharmaceuticals Group, based in Rockville, Maryland. Dr. Bryan's responsibilities at Shire included business development, licensing, and Project Management for Shire's bioavailability enhancement and oral controlled release drug delivery technologies as well as Management Team member.

Dr. Bryan now serves as Vice President of Business Development, Licensing and Project Management of Supernus Pharmaceuticals following the Management Team led acquisition of substantially all of the assets of Shire Laboratories to form a specialty pharmaceutical company.

Dr. Bryan received his B.S. degree in Zoology from Clemson University, Ph.D. degree in Pharmaceutics from the Medical University of South Carolina in 1991, and an Executive Management Certificate from the University of North Carolina Kenan-Flagler Business School in 1999.

He is a member of the Licensing Executives Society (LES), American Association of Pharmaceutical Scientists (AAPS), and Controlled Release Society (CRS) and serves as an Advisory Board member to IIR's Drug Delivery Partnerships Conference.

Padmanabh P. Bhatt, Ph.D.
Vice President of Pharmaceutical Sciences

Padmanabh P. Bhatt, Ph.D. is the Vice President of Pharmaceutical Sciences responsible for the Pharmaceutical Research and Development functions as well as Intellectual Property. He is a member of the executive team that transitioned over from Shire Laboratories, Inc. to Supernus Pharmaceuticals, Inc. Dr. Bhatt was Vice President of Advanced Drug Delivery at Shire since January 2003.

Dr. Bhatt's previous experience includes being the Vice President of R&D and Chief Technology Officer at Point Biomedical Corporation in San Carlos, California and Director of Technical Development at ALZA Corporation (now a Johnson & Johnson company) in Mountain View, California. Dr. Bhatt also held positions as Group Leader of Novel Drug Delivery at Dow Corning Corporation in Midland, Michigan and Senior Scientist at Hercon Laboratories in York, Pennsylvania.

Overall, Dr. Bhatt has more than 19 years of pharmaceutical industry experience in the fields of drug delivery, controlled release, product and technology development, clinical PK, and intellectual property.

Dr. Bhatt has B.Pharm. and M.Pharm. degrees from the University of Bombay, India. He then studied under Dr. Takeru Higuchi at the University of Kansas in Lawrence, Kansas, USA where he earned M.S. and Ph.D. degrees in Pharmaceutical Chemistry.

Christopher D. Breder, M.D., Ph.D.
Vice President, Clinical Development

Dr. Breder joined Supernus Pharmaceuticals in September 2006 as the Vice President of the Clinical Development group. Prior to joining Supernus, he served as Group Director, Neuroscience Global Clinical Research at Bristol-Myers Squibb in Wallingford, CT, where he worked for several years in a variety of Phase III/IV programs. These projects spanned across several areas including psychosis, depression, pharmacotherapy of alcoholism and metabolics. At Bristol-Myers Squibb, Dr. Breder also served as the Co-chairperson for a Neuroscience Exploratory Development Team. Before BMS, Chris was at Purdue Pharma LP, Division of Medical Research, where he worked as Clinical Leader for several projects that included the development of new formulations. At Purdue, he was also clinical representative to the licensing group and Strategic Therapeutic team. Dr. Breder also served as Assistant Professor in the Department of Anesthesiology, Division of Neuroanesthesiology, at the Columbia University, Presbyterian Hospital.

Dr. Breder completed his residency in anesthesiology, clinical fellowship in Neuroanesthesiology and post-doctoral fellowship in molecular neurobiology at the Johns Hopkins University. He obtained his Doctor of Medicine degree at The University of Chicago, Pritzker School of Medicine; his Doctor of Philosophy degree at The University of Chicago, Committee on Neurobiology; and his BS in Chemistry at The American University (Summa cum Laude).